Biotech Values

[oc631]

I simply didn’t think a drug so early in development could have been worth more than a few hundred million dollars in GILD’s valuation analysis.

PSI-938 was poised to enter late stage testing in 2H/12 pending results in the QUANTUM study. It was not in early development.